Project Title
TCR-αβ+ and CD19+ Depleted KIR/KIR Ligand-mismatched Haploidentical Hematopoietic Stem Cell Transplant and Zoledronate for Pediatric Relapsed/Refractory Hematologic Malignancies and High Risk Solid Tumors
Layman’s summary
Dr. Otto’s study proposes utilizing a ground-breaking, novel stem cell transplant method in children with relapsed and difficult to cure solid tumors that have not been controlled by conventional cancer therapy. It is expected to decrease the likelihood of cancer relapse and decrease the chance of life-threatening infections after transplant. The anti-cancer activity of some of the immune cells can be further stimulated with a medication called Zoledronate, which patients will receive after transplant.
Mario Otto
This Project By The Numbers
